Margaret G. Mcglynn

Ms. McGlynn joined the Novavax board of directors in 2020 and has extensive vaccine industry experience. She served as president and chief executive officer of the International AIDS Vaccine Initiative (IAVI) from 2011 through 2015, where she led extensive partnership efforts to advance the development, global launch and access to a broadly effective HIV vaccine. Previously, Ms. McGlynn spent more than two decades at Merck where she held roles of increasing responsibility, including president of Merck Vaccines and Infectious Diseases, and president, U.S. Hospital and Specialty Products Division. She is currently the president and board chair for HCU Network America, a patient advocacy organization focused on the rare genetic disease homocystinuria (HCU) and related disorders. She also serves on the boards of directors of Amicus Therapeutics and Vertex Pharmaceuticals and is a director of the non-profit organization, Life Science Cares Philadelphia. Ms. McGlynn received a bachelor of science degree in pharmacy, a master’s degree in business administration in marketing, and an honorary doctorate from the State University of New York at Buffalo.